Vagistat-1 is first OTC one-day vaginal yeast infection treatment.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS SQUIBB VAGISTAT-1 ONE-DAY OTC VAGINAL YEAST INFECTION TREATMENT to launch by spring in drug, food and mass market merchandisers. BMS received approval for the OTC 6.5% tioconazole vaginal yeast infection ointment on Feb. 11. The company filed a supplemental NDA (20-676) for U.S. OTC use of tioconazole for vaginal yeast infections in November 1995. Vagistat-1 has been approved for OTC marketing in the U.K. since January 1994.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning